急性冠脉综合征患者PCI术后短程双联抗栓后单用替格瑞洛的疗效观察

Efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome after PCI

目的:观察经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)的急性冠脉综合征(acute coronary syndrome,ACS)患者短程双联抗栓后单用替格瑞洛抗血小板治疗的临床疗效。方法:选取2018年10月至2021年12月我院及江苏省苏北人民医院接受过PCI术的ACS患者172例,根据患者服药情况分为3组:A组(单纯替格瑞洛组)50例;B组(阿司匹林肠溶片+替格瑞洛组)62例;C组(阿司匹林肠溶片+硫酸氢氯吡格雷组)60例。观察患者术后再发心绞痛、支架内再狭窄、再次血运重建、心衰、出血等情况。结果:3组之间术后再发心绞痛、支架内再狭窄、再次血运重建、心衰、出血无统计学差异。结论:PCI术后短程双抗后单用替格瑞洛抗血小板治疗患者缺血性事件、心衰无增加,而且可减少出血风险。

AIM:To observe the clinical efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome(ACS)treated with percutaneous coronary intervention(PCI).METHODS:A total of 172 patients with ACS who had undergone PCI from October 2018 to April 2022 in our hospital and Subei People's Hospital of Jiangsu Province were selected and divided into three groups according to the patients'medication status:50 patients in group A(tegretol alone group);62 patients in group B(aspirin enteric coated tablets+tegretol group);and 60 patients in group C(aspirin enteric coated tablets+clopidogrel hydrogen sulfate group).The patients were observed for postoperative recurrent angina pectoris,in-stent restenosis,revascularization,heart failure,and bleeding.RESULTS:There were no significant differences in postoperative recurrent angina,in-stent restenosis,re-hematologic reconstruction,heart failure,and bleeding between the 3 groups.CONCLUSION:There is no increase in ischemic events,heart failure in patients treated with tegretol antiplatelet therapy alone after a short course of dual antibiotics after PCI and it reduces risk of bleeding.